Results 21 to 30 of about 459,966 (302)

Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS [PDF]

, 2012
Despite significant progress in the development of therapies for relapsing MS, progressive MS remains comparatively disappointing. Our objective, in this paper, is to review the current challenges in developing therapies for progressive MS and identify ...
Salvetti, M, D. Brown, T. Coetzee, K. Sharrock, Lee, K, Brown, D, Feinstein, A, Thompson, A, K. Zuidwijk, D. Chandraratna, Kapoor, R, Fox, RJ, Zuidwijk, K, K. Lee, A. Thompson, G. Comi, Toosy, A, Baneke, P, Browne, P, Sharrock, K, O. Ciccarelli, P. Browne, A. Feinstein, Comi, G, R. J. Fox, Chandraratna, D, P. Zaratin, Baker, D, R. Kapoor, Ciccarelli, O, Zaratin, P, P. Baneke, Coetzee, T, D. Baker, SALVETTI, Marco, A. Toosy   +35 more
core   +1 more source

Author Correction: A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis

Nature Communications, 2019
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
International Multiple Sclerosis Genetics Consortium
doaj   +1 more source

No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]

Neurology and Therapy, 2023
The emergence of high-efficacy therapies for multiple sclerosis (MS), which target inflammation more effectively than traditional disease-modifying therapies, has led to a shift in MS management towards achieving the outcome assessment known as no ...
Scott D. Newsome, Cherie Binns, Ulrike W. Kaunzner, Seth Morgan, June Halper   +4 more
doaj   +1 more source

Real-World Efficacy of COVID-19 Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab in People with Multiple Sclerosis

Vaccines, 2023
Vaccines against the SARS-CoV-2 virus were authorized for use by the Food and Drug Administration (FDA) in the United States and have proven effective for the prevention of morbidity and death from COVID-19.
Luke B. Elias, Aliya Jaber, Margarita Manzano, Mark Leekoff, Andrew Sylvester, Matthew A. Tremblay   +5 more
doaj   +1 more source

Radiologically isolated syndrome and multiple sclerosis [PDF]

, 2017
Background Incidental white matter lesions (WML) are increasingly seen on brain magnetic resonance imaging (MRI) in clinical practice. Demyelination consistent with MS is seen in 0.1–0.7% of the population as evident by autopsy and MRI studies.
AlKhawajah, Mona Marwan, B. Yamout, M. Al Khawajah, Yamout, Bassem I.   +3 more
core   +1 more source

Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study

Frontiers in Neurology, 2023
BackgroundAlemtuzumab (ALZ) is a humanized monoclonal antibody approved for the treatment of patients with highly active relapsing-remitting multiple sclerosis (RRMS) administered in two annual courses.
Sara Eichau, Rocío López Ruiz, María Ruíz de Arcos, Juan Luis Ruiz-Peña, Guillermo Navarro, Miguel Ángel Calleja, José Luis Moreno-Amador, Julio Dotor García-Soto   +7 more
doaj   +1 more source

Multiple sclerosis [PDF]

Primary Care: Clinics in Office Practice, 2004
Multiple sclerosis is a complex genetic disease associated with inflammation in the CNS white matter thought to be mediated by autoreactive T cells. Clonal expansion of B cells, their antibody products, and T cells, hallmarks of inflammation in the CNS, are found in MS.
Kathleen, Hawker, Elliot, Frohman
openaire   +4 more sources

Family Perspectives on Clinical Research for Pediatric Multiple Sclerosis: Enhancing Equity

Journal of Patient Experience, 2021
Pediatric new drug trials are federally mandated, but family perspectives in multiple sclerosis (MS) research are limited. Due to MS chronicity and long-term medical system involvement, we obtained family views on research priorities and optimized ...
Leslie A Mandel PhD, MA, MS, Ellen O’Donnell PhD, Katia Canenguez PhD, EdM, Paola B Castro-Mendoza BSc, MSc, Tim Lotze MD, Emmanuelle Waubant MD, PhD, Bianca Weinstock-Guttmann MD, Tanuja Chitnis MD   +7 more
doaj   +1 more source

Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland [PDF]

, 2018
Background: Recent studies emphasise the importance of timely diagnosis and early initiation of disease-modifying treatment in the long-term prognosis of multiple sclerosis.
Calabrese, Pasquale, Rodgers, S., Kaufmann, Marco; https://orcid.org/, Kuhle, J., Puhan, M.A., Puhan, Milo A, Kuhle, Jens, Puhan, M. A., Kamm, Christian P, Kesselring, Jürg, Rodgers, Stephanie, Pot, Caroline, Steinemann, Nina, von Wyl, Viktor, Kamm, C.P., von Wyl, V., Salmen, A., Pot, C., Salmen, Anke, Steinemann, N., Kaufmann, M., Chan, A., Kamm, Christian Philipp, Chan, Andrew, Gobbi, C., Gobbi, Claudio, Kesselring, J., Calabrese, P.   +27 more
core   +1 more source

The genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: a multicenter case-control study.

PLoS ONE, 2011
BackgroundIn the recently published meta-analysis of multiple sclerosis genome-wide association studies De Jager et al. identified three single nucleotide polymorphisms associated to MS: rs17824933 (CD6), rs1800693 (TNFRSF1A) and rs17445836 (61.5 kb from
International Multiple Sclerosis Genetics Consortium
doaj   +1 more source